| abstract |
Method of predicting survival outcome based on one or more samples of diffuse large B-cell lymphoma (DLBCL), a method comprising: a) isolating gene expression products from one or more DLBCL biopsy samples from a subject treated with a therapeutic regimen that includes chemotherapy and rituximab (R-CHOP); b) obtain a gene expression profile from the gene expression products, in which the expression profile comprises an expression level for each of at least 31 of the genes listed in table 1 for the gene expression signature of germ center B cells (GCB) and at least 226 of the genes listed in Table 1 for the signature of stromal-1 gene expression; c) determine a GCB signature value and a stromal signature value-1 from the gene expression profile, in which the GCB signature value is an average of the expression levels of the at least 31 genes listed in Table 1 for the GCB gene expression signature and the stromal signature value-1 is an average of the expression levels of the at least 226 genes listed in Table 1 for the stromal gene expression signature-1; d) calculate a survival prediction factor score> = A - [(x) * (the GCB signature value)] - [(y) * (the stromal signature value-1)], in which A is a deviation term, (x) is a scale factor between 0.200 and 0.625, and (y) is a scale factor between 0.800 and 1.250, and e) determine the survival outcome for the subject based on the score of survival prediction factor calculated in step d) for any fixed equal value of A and for any equal fixed value of (x) e (y), in which a lower survival prediction factor score indicates a result of More favorable survival and a higher survival prediction factor score indicates a less favorable survival outcome for the subject. |